Login to Your Account

Medarex, FDA Reach Accord On Phase III Melanoma SPA

By Randall Osborne

Tuesday, August 24, 2004
Medarex Inc. and the FDA have agreed on a special protocol assessment for the pivotal Phase III trial with the fully human antibody MDX-010 plus MDX-1379, a gp100 melanoma peptide vaccine, against patients with unresectable metastatic disease who can't tolerate first-line therapy. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription